These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12094708)

  • 1. [Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH].
    Noguchi K; Takeda M; Hosaka M; Kubota Y
    Hinyokika Kiyo; 2002 May; 48(5):269-73. PubMed ID: 12094708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H; Yano M; Awa Y; Nakatsu H; Egoshi K; Mikami K; Ota S; Okano T; Hamano S; Ohki T; Furuya Y; Ichikawa T
    Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical study of allylestrenol (Perselin) on patients with prostatic hypertrophy].
    Fukuoka H; Ishibashi Y; Shiba T; Tuchiya F; Sakanishi S
    Hinyokika Kiyo; 1993 Jul; 39(7):679-83. PubMed ID: 7689782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical effects of allylestrenol on prostatic hypertrophy].
    Kohri K; Kurita T; Iguchi M; Kataoka K
    Hinyokika Kiyo; 1986 Mar; 32(3):486-92. PubMed ID: 2425611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia.
    Noguchi K; Suzuki K; Teranishi J; Kondo K; Kishida T; Saito K; Uemura H; Kubota Y
    Hinyokika Kiyo; 2006 Jul; 52(7):527-30. PubMed ID: 16910584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of interruption of therapy with allylestrenol in patients with benign prostatic hypertrophy.
    Noguchi K; Harada M; Masuda M; Takeda M; Kinoshita Y; Fukushima S; Miyai K; Fukuoka H; Hosaka M
    Int J Urol; 1998 Sep; 5(5):466-70. PubMed ID: 9781436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
    Te AE; Malloy TR; Stein BS; Ulchaker JC; Nseyo UO; Hai MA
    BJU Int; 2006 Jun; 97(6):1229-33. PubMed ID: 16686717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical effect of allylestrenol on benign prostatic hypertrophy].
    Tajima A; Aso Y; Ushiyama T; Hata M; Kambayashi T; Ohmi Y; Masuda H; Nakahara M; Kitagawa M; Suzuki A
    Hinyokika Kiyo; 1986 Mar; 32(3):477-85. PubMed ID: 2425610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
    Chung BH; Hong SJ
    BJU Int; 2006 Jan; 97(1):90-5. PubMed ID: 16336335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan.
    Tsai YS; Lan SK; Ou JH; Tzai TS
    Clin Ther; 2007 Apr; 29(4):670-82. PubMed ID: 17617290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical effects of beta-sitosterol (phytosterol) on benign prostatic hyperplasia: preliminary study].
    Kobayashi Y; Sugaya Y; Tokue A
    Hinyokika Kiyo; 1998 Dec; 44(12):865-8. PubMed ID: 10028431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin].
    Suzuki H; Ohnishi T; Ikemoto I; Ohishi Y; Suzuki Y; Yamazaki H
    Hinyokika Kiyo; 2001 Feb; 47(2):77-81. PubMed ID: 11280890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The clinical efficacy of epristeride in the treatment of benign prostatic hyperplasia].
    Ju XB; Wu HF; Hua LX; Zhang W; Li J
    Zhonghua Nan Ke Xue; 2002; 8(1):42-4. PubMed ID: 12479047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Transurethral microwave thermotherapy for benign prostatic hyperplasia].
    Murayama K; Hisada K
    Hinyokika Kiyo; 2000 Nov; 46(11):799-802. PubMed ID: 11193300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia].
    Song Y; Li NC; Wang XF; Ma LL; Wan B; Hong BF; Na YQ
    Zhonghua Nan Ke Xue; 2005 Sep; 11(9):674-6. PubMed ID: 16209208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study of allylestrenol (Org AL-25) on patients with prostatic hypertrophy--transrectal ultrasonography and urodynamic examination].
    Ohyama M; Tanifuji T; Haraguchi C; Fujii N; Higaki Y; Yoshida H; Imamura K
    Hinyokika Kiyo; 1986 Apr; 32(4):649-59. PubMed ID: 2426933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photoselective vaporization of the prostate in the treatment of benign prostatic hyperplasia.
    Fu WJ; Hong BF; Yang Y; Cai W; Gao JP; Wang CY; Wang XX
    Chin Med J (Engl); 2005 Oct; 118(19):1610-4. PubMed ID: 16232345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Stief CG; Porst H; Neuser D; Beneke M; Ulbrich E
    Eur Urol; 2008 Jun; 53(6):1236-44. PubMed ID: 18281145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia].
    Noguchi K; Uemura H; Takeda M; Sekiguchi Y; Ogawa K; Hosaka M
    Hinyokika Kiyo; 2000 Sep; 46(9):605-7. PubMed ID: 11107528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.